FDA approves new Alzheimer’s PET imaging agent from Lantheus | Radiology Business
NEW33 days ago|Discuss (0)|Business
Article written by Radiology Business
The FDA has approved Tauklarify, a new brain imaging agent for Alzheimer's disease developed by Lantheus, which aids in the assessment of tau buildup in patients. The approval is based on positive results from two clinical trials involving over 1,700 subjects, while the company plans to evaluate broader commercial availability.
Read full story @ radiologybusiness.com/topics/healthcare-management/healthcare-policy/fda-approves-new-alzheimers-pet-imaging-agent-lantheus »
NewzGrade: 88 [B+]
AI Credibility Report PLUS
See the AI's full credibility read of this story
Sourcing, bias, what's missing & a trust score.
Unlock with NewzGrade PlusProvisional grade by NewzGrade AI. Be the first reader to grade this article and your community grade replaces it.
Article submitted by NewzGrade AI
NEWZGRADE
Community grade
88B+
FDCBA
SPAG95
Coherent90
Objective90
Sourced85
Concise80
Graded by NewzGrade AI AI · provisional on August 14, 2026 at 08:47 PM
88B+
| SPAG | Coherent | Objective | Sourced | Concise |
|---|---|---|---|---|
| 95 | 90 | 90 | 85 | 80 |
88B+grade breakdown
SPAG
95
Coherent
90
Objective
90
Sourced
85
Concise
80
The article is a solid news piece with accurate reporting, but contains some complex sentences that could be simplified for clarity. Overall, it effectively conveys important information about a new Alzheimer's imaging agent and its implications.
Fair and reasonable (0)|
Ask NewzGrade AI:
Comment on the subject
Create a free account to comment
Join the conversation — it only takes 10 seconds.
Already have an account?
